Profile data is unavailable for this security.
About the company
Bristol-Myers Squibb Company is a biopharmaceutical company. The Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company offers products for a range of therapeutic classes, which include oncology, immunology, cardiovascular and fibrosis. The Company’s pharmaceutical products include chemically-synthesized or small molecule drugs and products produced from biological processes, called biologics. Small molecule drugs are administered orally in the form of a pill or tablet. Biologics are administered to patients through injections or by infusion. The Company’s products include Revlimid, Eliquis, Opdivo, Orencia, Pomalyst/Imnovid, Sprycel, Yervoy, Abraxane, Empliciti, Reblozyl, Inrebic, Onureg, Zeposia, Vidaza, Baraclude and Breyanzi. Its products are sold to wholesalers, distributors, pharmacies, retailers, hospitals, clinics and government agencies.
- Revenue in USD (TTM)47.14bn
- Net income in USD6.62bn
- Incorporated1933
- Employees32.20k
- LocationBristol-Myers Squibb Co430 E. 29Th Street, 14 FloorNEW YORK 10016United StatesUSA
- Phone+1 (212) 546-4000
- Fax+1 (302) 655-5049
- Websitehttps://www.bms.com/
Mergers & acquisitions
| Acquired company | BMY:NYQ since announced | Transaction value |
|---|---|---|
| Turning Point Therapeutics Inc | -2.38% | 3.97bn |
| Aurinia Pharmaceuticals Inc | 26.76% | -- |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Zoetis Inc | 8.00bn | 2.09bn | 82.18bn | 12.10k | 39.63 | 17.87 | 32.28 | 10.28 | 4.41 | 4.41 | 16.85 | 9.77 | 0.5744 | 1.18 | 6.50 | 660,743.80 | 15.00 | 13.79 | 18.40 | 16.04 | 70.44 | 68.75 | 26.12 | 23.94 | 1.46 | 11.64 | 0.5894 | 22.53 | 16.49 | 9.73 | 24.36 | 19.93 | 17.17 | 20.72 |
| Amgen, Inc. | 26.38bn | 6.58bn | 131.55bn | 24.20k | 20.86 | 54.46 | 14.37 | 4.99 | 11.80 | 11.80 | 47.50 | 4.52 | 0.4432 | 1.48 | 5.38 | 1,090,248.00 | 11.05 | 11.07 | 14.32 | 13.40 | 75.75 | 79.29 | 24.92 | 30.88 | 1.17 | 7.46 | 0.9379 | 49.28 | 2.18 | 2.47 | -18.87 | -5.26 | 1.01 | 11.97 |
| Bristol-Myers Squibb Co | 47.14bn | 6.62bn | 153.99bn | 32.20k | 23.97 | 4.72 | 9.00 | 3.27 | 3.01 | 3.01 | 21.49 | 15.27 | 0.4465 | 4.58 | 6.00 | 1,464,099.00 | 6.29 | 2.67 | 7.76 | 3.29 | 79.22 | 74.18 | 14.08 | 6.54 | 1.34 | 5.55 | 0.5629 | 163.84 | 9.09 | 19.01 | 177.58 | 9.43 | -4.35 | 5.22 |
| Merck & Co., Inc. | 57.17bn | 16.64bn | 221.04bn | 68.00k | 13.33 | -- | 14.34 | 3.87 | 6.56 | 6.53 | 22.53 | -- | -- | -- | -- | 840,720.60 | -- | 7.61 | -- | 10.14 | 71.56 | 70.92 | 29.13 | 16.06 | -- | 110.21 | -- | 86.06 | 17.31 | 4.12 | 173.18 | 25.79 | 22.48 | 7.49 |
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Mar 2022 | 189.63m | 8.91% |
| BlackRock Fund Advisorsas of 31 Mar 2022 | 105.02m | 4.93% |
| SSgA Funds Management, Inc.as of 31 Mar 2022 | 94.43m | 4.44% |
| JPMorgan Investment Management, Inc.as of 31 Mar 2022 | 62.33m | 2.93% |
| Fidelity Management & Research Co. LLCas of 31 Mar 2022 | 48.82m | 2.29% |
| Wellington Management Co. LLPas of 31 Mar 2022 | 42.52m | 2.00% |
| Geode Capital Management LLCas of 31 Mar 2022 | 37.56m | 1.76% |
| Dodge & Coxas of 31 Mar 2022 | 27.00m | 1.27% |
| Northern Trust Investments, Inc.(Investment Management)as of 31 Mar 2022 | 24.09m | 1.13% |
| Capital Research & Management Co. (International Investors)as of 31 Mar 2022 | 22.90m | 1.08% |
